Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II–independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways

Fu, Xuanhe; Xu, Mingkai; Song, Yiling; Li, Yongqiang; Zhang, Huiwen; Zhang, Jinghai; Zhang, Chenggang

doi:10.1074/jbc.ra118.003668

Cited by 20 publications

(18 citation statements)

References 45 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that IL-2 and IL-2 receptor (IL-2R) provides an important signal for T cell activation through JAK1-STAT5 signaling pathway 11 . IL-2R has three subunits: IL-2Rα, IL-2Rβ, and IL-2Rγc, and the activated T cells can simultaneously express α, β, and γc chain and form a high-affinity receptor 12 .…”

Section: The Expression Of Il2 Receptor Jak1 Stat5 In Patients Withmentioning

confidence: 99%

The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia

Wang

Ouyang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Although most patients with COVID-19 pneumonia have a good prognosis, some patients develop to severe or critical illness, and the mortality of critical cases is up to 61.5%. However, specific molecular information about immune response in critical patients with COVID-19 is poorly understood. A total of 54 patients were enrolled and divided into three groups, among which 34 were common, 14 were severe, and 6 were critical. The constitution of peripheral blood mononuclear cells (PBMC) in patients was analyzed by CyTOF. The profile of cytokines was examined in plasma of patients using luminex. The IL-2 signaling pathway was investigated in the PBMC of patients by qRT-PCR. The count and percentage of lymphocytes were significantly decreased in critical patients compared to common and severe patients with COVID-19 pneumonia. The count of T cells, B cells, and NK cells was remarkably decreased in critical patients compared to normal controls. The percentage of CD8 + T cells was significantly lower in critical patients than that in common and severe patients with COVID-19 pneumonia. The expression of IL-2R, JAK1, and STAT5 decreased in PBMC of common, severe, and critical patients, but IL-2 level was elevated in severe patients and decreased in critical patients with COVID-19 pneumonia. The decrease of CD8 + T cells in critical patients with COVID-19 pneumonia may be related to the IL-2 signaling pathway. The inhibition of IL-2/IL-2R gives rise to CD8 + T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.

show abstract

Section: The Expression Of Il2 Receptor Jak1 Stat5 In Patients Withmentioning

confidence: 99%

The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia

Wang

Ouyang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…The primers used in this study are listed in Table 1. The different gene expression levels were calculated using the 2 −ΔΔCt method, as previously described 16 . Statistical analysis.…”

Section: Reverse Transcription-pcr Analysis Of the Gene Expression Ofmentioning

confidence: 99%

Effect of IL-34 on T helper 17 cell proliferation and IL-17 secretion by peripheral blood mononuclear cells from rheumatoid arthritis patients

Lei

Gao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Interleukin (IL)-34 is a new pro-inflammatory cytokine with elevated expression in rheumatoid arthritis (RA) patients. Our previous study showed that the frequency of T helper 17 (Th17) cells was also elevated in RA patients. Our study aimed to determine the effects of IL-34 on the proliferation, transcription factor expression and cytokine secretion of different subgroups of CD4 + T cells [Th1, Th2, Th17 and regulatory T (Treg) cells] in RA patients. Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of 10 RA patients and stimulated with different concentrations of recombinant human (rh) IL-34 (0, 25, 50 and 100 ng/ml). Flow cytometry was used to determine the frequencies of the 4 subgroups of CD4 + T cells. Reverse transcription-PCR, western blotting and enzyme-linked immunosorbent assays were used to determine the mRNA and protein expression levels of transcription factors and cytokines. As a result, the frequency of Th17 cells was obviously increased under IL-34 stimulation. Moreover, the expression of the transcription factor retinoic acid-related orphan receptor (ROR-γt) and secretion of IL-17 by PBMCs were increased by stimulation with IL-34. However, there were no effects of IL-34 on transcription factors or cytokine secretion in Th1, Th2 and Treg cells. In conclusion, IL-34 can improve the proliferation of Th17 cells and expression of IL-17 in RA patients.

show abstract

“…We also found that the proportion of CD8+ T cells was also significantly decreased after SARS-CoV-2 infection ( Figure 7 ). JAK1 was involved in the activation of T cells, and its low expression was correlated with a decrease in CD8+ T cells in patients with COVID-19 pneumonia, especially in those with severe and critical cases [ 39 , 40 ]. These results indicate that SARS-CoV-2 infection may reduce the proportion of CD8+ T cells in LUAD cell lines by inhibiting the expression of JAK1.…”

Section: Discussionmentioning

confidence: 99%

Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma

Cai

Deng²,

Luo

et al. 2020

Aging

View full text Add to dashboard Cite

Janus kinase 1 (JAK1) is a member of the JAK family, which plays an essential and non-redundant role in tumorigenesis. However, the potential role of JAK1 in immune infiltration and prognosis of lung adenocarcinoma (LUAD) remains unclear. The mRNA expression and methylation level of JAK1 in LUAD were examined using the Oncomine and The Cancer Genome Atlas (TCGA) databases, respectively. The correlations between JAK1 expression and its methylation level and clinicopathological parameters were analyzed. The Kaplan–Meier plotter database was used to evaluate the prognostic value of JAK1 in LUAD. The signaling pathways associated with JAK1 expression were identified by performing a GSEA. The CIBERSORT and TIMER databases were used to analyze the correlations between JAK1 and tumor-infiltrating immune cells. In addition, the JAK1 expression and proportion of immune cells in LUAD cell lines were analyzed. The JAK1 expression was remarkably decreased in patients with LUAD and significantly correlated with the clinical features of patients with LUAD. The JAK1 methylation level was increased and negatively correlated with its mRNA expression. A decrease in JAK1 expression was correlated with poor prognosis. The results of GSEA showed that cell adhesion, tumorigenesis, and immune-related signaling pathways were mainly enriched. JAK1 was positively associated with tumor-infiltrating immune cells, and the results of CIBERSORT analysis suggested that JAK1 was correlated with monotypes and M1 macrophages. The results of the TIMER database analysis confirmed that JAK1 was closely associated with the gene markers of M1 macrophages. Thus, JAK1 may serve as a potential prognostic biomarker in LUAD and is associated with immune infiltration.

show abstract

Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II–independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways

Cited by 20 publications

References 45 publications

The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia

The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia

Effect of IL-34 on T helper 17 cell proliferation and IL-17 secretion by peripheral blood mononuclear cells from rheumatoid arthritis patients

Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma

Contact Info

Product

Resources

About